These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 10068269)
1. Can we cure indolent lymphomas? Cabanillas F Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2655-9. PubMed ID: 10068269 [TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
3. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536 [TBL] [Abstract][Full Text] [Related]
4. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma. Galimberti S; Marasca R; Caracciolo F; Fazzi R; Papineschi F; Benedetti E; Guerrini F; Morabito F; Oliva E; Di Renzo N; Federico M; Petrini M; Torelli G; Bone Marrow Transplant; 2002 Apr; 29(7):581-7. PubMed ID: 11979307 [TBL] [Abstract][Full Text] [Related]
5. The role of mitoxantrone in the treatment of indolent lymphomas. Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217 [TBL] [Abstract][Full Text] [Related]
6. [Treatment of primary mediastinal large B-cell lymphomas]. Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas. Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762 [TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737 [TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. Longo DL; Duffey PL; Gribben JG; Jaffe ES; Curti BD; Gause BL; Janik JE; Braman VM; Esseltine D; Wilson WH; Kaufman D; Wittes RE; Nadler LM; Urba WJ Cancer J; 2000; 6(3):146-50. PubMed ID: 10882329 [TBL] [Abstract][Full Text] [Related]
10. New treatment strategies in lymphomas: aggressive lymphomas. Coiffier B Ann Hematol; 2004; 83 Suppl 1():S73-4. PubMed ID: 15124681 [TBL] [Abstract][Full Text] [Related]
11. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272 [TBL] [Abstract][Full Text] [Related]
12. Novel treatment strategies in follicular lymphoma. Buske C; Dreyling H; Unterhalt M; Hiddemann W Ann Hematol; 2004; 83 Suppl 1():S72. PubMed ID: 15124680 [TBL] [Abstract][Full Text] [Related]
13. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727 [TBL] [Abstract][Full Text] [Related]
14. [Principles of treatment and military medical examination of the patients with indolent Non-Hodgkin's lymphomas]. Seriakov AP; Ushakov II; Ardashev VN; Mazurov VI; Korotkiĭ AN Voen Med Zh; 2003 Oct; 324(10):34-41, 96. PubMed ID: 14671893 [TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma. Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111 [TBL] [Abstract][Full Text] [Related]
16. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity]. Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624 [TBL] [Abstract][Full Text] [Related]
17. Purine analogue combinations for indolent lymphomas. Di Bella N; Ravandi F Semin Hematol; 2006 Apr; 43(2 Suppl 2):S11-21. PubMed ID: 16549109 [TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054 [TBL] [Abstract][Full Text] [Related]
19. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Czuczman MS Semin Oncol; 1999 Oct; 26(5 Suppl 14):88-96. PubMed ID: 10561023 [TBL] [Abstract][Full Text] [Related]
20. The role of interferon in the therapy of malignant lymphoma. McLaughlin P Biomed Pharmacother; 1996; 50(3-4):140-8. PubMed ID: 8881370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]